journal article·2023-12-31Open access

IgG antibodies mediated gold nanoparticles conjugated to methotrexate as targeted chemotherapy for lung cancer

Asad Syed, Abu Baker, Mohamed Mohany, Abdallah M. Elgorban, Mohd Sajid Khan, Salim S. Al-Rejaie

Abstract

Vincamine, a natural chemical, was used as a reducing agent in the synthesis of IgG antibodies mediated biogenic gold nanoparticles (IgGAuNPs). Eventually, the synthesised IgGAuNPs were bioconjugated with the chemotherapeutic drug methotrexate (MTX-IgGAuNPs). The IgG isotype can target cancer cells through polymorphic Fc gamma receptors (FcγRs) and have therapeutic effects. They can restrict cell division by inhibiting different intracellular signal transduction pathways and activating NK cells and macrophages through antibody-dependent cellular cytotoxicity and macrophage-mediated antibody-dependent phagocytosis, respectively. Further, IgGAuNPs and MTX-IgGAuNPs were characterised by physical techniques. Moreover, 3D conformational changes in the structure of IgG were analysed by fluorescence spectroscopy during and after the synthesis of IgGAuNPs. Furthermore, the IgGAuNPs and MTX-IgGAuNPs were effective against lung cancer (A549 cells), while they were found to be non-toxic against normal cells (NRK cells). The effectiveness of IgGAuNPs and MTX-IgGAuNPs was examined by MTT cytotoxicity assay, DCFDA method for the production of ROS, and release of Cyt-c from the mitochondria for caspase-3-mediated apoptosis. Moreover, the confirmation of internalisation of particles into the nucleus was examined under the DAPI assay, and it was found that particles caused nuclear fragmentation, which was also an indication of apoptosis.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Monoclonal and Polyclonal Antibodies Research · Nanoparticle-Based Drug Delivery · Glycosylation and Glycoproteins Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Botany and Microbiology, College of Science, King Saud University, P.O. 2455, Riyadh 11451, Saudi Arabia

Nanomedicine & Nanobiotechnology Lab, Department of Biosciences, Integral University, Lucknow, 226026 India

Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. 55760, Riyadh 11451, Saudi Arabia

Center of Excellence in Biotechnology Research, King Saud University, Riyadh, Saudi Arabia

Funding

Ministry of Education

References (35)

Show source-provided references
1. 10.1166/jbn.2021.305310.1166/jbn.2021.3053 ↗
2. 10.3390/ijms2111374210.3390/ijms21113742 ↗
3. 10.1007/s10147-017-1117-y10.1007/s10147-017-1117-y ↗
4. 10.1016/j.addr.2022.11452510.1016/j.addr.2022.114525 ↗
5. 10.1021/acsanm.9b0260310.1021/acsanm.9b02603 ↗
6. 10.1016/j.tips.2009.08.00410.1016/j.tips.2009.08.004 ↗
7. 10.1155/2019/370251810.1155/2019/3702518 ↗
8. 10.1016/j.addr.2013.11.00910.1016/j.addr.2013.11.009 ↗
9. 10.1053/j.seminoncol.2014.08.00110.1053/j.seminoncol.2014.08.001 ↗
10. Heemskerk N · J Clin Invest · 2021 · 131 · e13468010.1172/JCI134680 ↗
11. 10.1038/nrc393010.1038/nrc3930 ↗
12. 10.1038/nri.2017.9710.1038/nri.2017.97 ↗
13. 10.1038/s41577-018-0061-z10.1038/s41577-018-0061-z ↗
14. 10.1093/intimm/dxx04110.1093/intimm/dxx041 ↗
15. 10.18632/oncotarget.2355310.18632/oncotarget.23553 ↗
16. 10.1016/j.ijbiomac.2020.04.11210.1016/j.ijbiomac.2020.04.112 ↗
17. 10.1159/00009596910.1159/000095969 ↗
18. 10.1016/j.saa.2010.05.02110.1016/j.saa.2010.05.021 ↗
19. 10.1371/journal.pone.027239610.1371/journal.pone.0272396 ↗
20. 10.1016/j.colsurfb.2017.09.01710.1016/j.colsurfb.2017.09.017 ↗
21. 10.1128/JB.187.18.6265-6272.200510.1128/JB.187.18.6265-6272.2005 ↗
22. 10.1016/j.colsurfa.2022.12859810.1016/j.colsurfa.2022.128598 ↗
23. 10.1007/s00604-003-0174-210.1007/s00604-003-0174-2 ↗
24. 10.1016/j.micpath.2020.10446710.1016/j.micpath.2020.104467 ↗
25. Berne BJ · 2000
26. 10.1016/j.chemphyslip.2004.04.00310.1016/j.chemphyslip.2004.04.003 ↗
27. 10.1016/s0022-1759(02)00325-310.1016/s0022-1759(02)00325-3 ↗
28. 10.3390/ijms2110348310.3390/ijms21103483 ↗
29. Senapati S · Target Ther · 2018 · 3 · 1
30. Nejadmoghaddam M-R · Avicenna J Med Biotechnol · 2019 · 11 · 3
31. 10.3390/ijms1809179710.3390/ijms18091797 ↗
32. 10.1016/j.techfore.2007.04.00310.1016/j.techfore.2007.04.003 ↗
33. 10.1073/pnas.121689311010.1073/pnas.1216893110 ↗
34. 10.1038/s41598-021-86762-610.1038/s41598-021-86762-6 ↗
35. 10.1074/jbc.274.11.721610.1074/jbc.274.11.7216 ↗